PBYI News and Press, Puma Biotechnology Inc From 07/27/20

Data published online in Gynecologic Oncology Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that data from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the safety and efficacy of neratinib in HER2 -mutated cancers, ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX® (neratinib) in Malaysia from the Drug Control Agency (DCA), under Malaysia’s Ministry of Healt...

Puma Biotechnology (PBYI) recently reported their Q1 earnings with a beat on EPS and revenue. Puma reported $51.2M in total revenue for Q1, which consisted of $2M in license revenue, $0.6M from royalties, and $48.6M from NERLYNX net sales. Unfortunately, NERLYNX sales were down from the $5...

Image source: The Motley Fool. Puma Biotechnology Inc   (NASDAQ: PBYI) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading

Puma Biotechnology, Inc. (PBYI) Q1 2020 Earnings Conference Call May 07, 2020 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chief Executive Officer, President & Chairman of the Board Maximo Nougues - Chief Financia...

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Puma Biotechnology (NASDAQ: PBYI ) Q1 results : More news on: Puma Biotechnology, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more ...

Puma Biotechnology (NASDAQ: PBYI ): Q1 Non-GAAP EPS of -$0.20 beats by $0.48 ; GAAP EPS of -$0.43 beats by $0.34 . More news on: Puma Biotechnology, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2020. Unless otherwise stated, all comparisons are for the first quarter of 2020 compared to the first quarter of 2019. Product revenue, net consists ent...

Puma Biotechnology (NASDAQ: PBYI ) announces that China's National Medical Products Administration has approved Nerlynx (neratinib) for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuv...